Pulmonx Corp Q2 revenue falls, but beats estimates

Pulmonx

29/07/2026 21:37

Overview
US lung disease device maker's Q2 revenue fell 5% but beat analyst expectations
Net loss for Q2 narrowed 34% yr/yr as cost realignment reduced expenses
International revenue declined due to lack of China sales; excluding China, international revenue grew 12%

Outlook
Pulmonx expects 2026 revenue in the range of $90 mln to $92 mln
Company now sees 2026 gross margin at approximately 76%
Pulmonx expects 2026 operating expenses between $109 mln and $111 mln

Result Drivers
CHINA SALES IMPACT - International revenue declined due to lack of sales into China as co awaited registration renewal
COST REALIGNMENT - Reduced operating expenses and net loss attributed to cost realignment efforts
GROSS MARGIN EXPANSION - Achieved record gross margin of 78% in Q2, up from 72% a year earlier

Company press release: ID:nGNX4v3Qfj

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$22.76 mln
$22.40 mln (5 Analysts)
Q2 Loss Per Share
 
$0.24
 
Q2 Net Loss
 
$10.08 mln
 
Q2 Gross Profit
 
$17.74 mln
 
Q2 Income From Operations
 
-$9.06 mln
 
Q2 Pretax Loss
 
$9.95 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Pulmonx Corp is $3.00, about 140% above its July 28 closing price of $1.25

Reuters Recommended Reads
July 29 - Boston Scientific trims annual profit forecast on softer Watchman device demand
July 29 - GE HealthCare tops quarterly estimates, weighs patient care unit sale
July 28 - Philips falls 9% as weak orders, China concerns overshadow outlook hike

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)